Biocon A.I CyberSecurity Scoring
12/09/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Biocon in 2026.
No incidents recorded for Biocon in 2026.
No incidents recorded for Biocon in 2026.
Biotechnology Research
A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ago, is driven by an unrelenting commitment to improve public health worldwide. Since 1963, we've been paving the way in the field of in vitro diagnostics and have contributed greatly to improving public health and making the world a healthier place. The solutions that our teams imagine, develop and manufacture are key to enable healthcare professionals and industry players to make confident decisions to improve patient outcome and ensure consumer safety.
At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines
About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation
Avantor® is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. More than 14,500 strong, our associates are passionate about our mission to set science in motion to create a better world. We share enthusiasm for innovation, excellence, and achievement. Whether we are collaborating with our customers to advance science or solve multifaceted problems, we help them reach their goals more efficiently and effectively. Visit our website to learn more about Avantor.
Fortrea (Nasdaq: FTRE) is a leading global clinical research organization (CRO) dedicated to providing innovative clinical development solutions to the life sciences industry. With over 30 years of clinical research experience, Fortrea has evolved from Covance and Labcorp into a pureplay CRO built for biotech, biopharma, medical device and diagnostic innovators. Fortrea collaborates with both emerging and established companies to deliver agile, fit-for-purpose full service (FSO), functional service (FSP) and hybrid solutions. Fortrea provides comprehensive Phase I-IV clinical trial management, clinical pharmacology, and consulting services, backed by deep experience in more than 20 therapeutic areas. Operating in approximately 100 countries, our diverse and talented team brings scientific rigor, operational excellence, and a strong investigator site network to every trial. By combining the best of our legacy experience with forward-thinking innovation, Fortrea brings predictability to clinical trial execution and helps transform aspirations into outcomes. Together, exceptional is possible. Learn more at Fortrea.com
NIH is the only agency of its kind. We impact the health of the country and the world through unique and innovative medical research. Did you know that NIH is the largest public funder of biomedical research in the world, investing more than $32 billion a year to enhance life, and reduce illness and disability? NIH funded research has led to breakthroughs and new treatments, helping people live longer, healthier lives, and building the research foundation that drives discovery. Whether you are graduating with a bachelor's degree, working on your doctoral degree, entering the workforce for the first time, or changing careers, NIH offers a place for you to start and plenty of room to grow your career. When you join us, you’re not just advancing your career — you’re driving the health of our country forward. Official LinkedIn Account of the NIH. Privacy policy: http://go.usa.gov/x9svN Comment policy: https://bit.ly/3G6xq94 Engagement ≠ endorsement
Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. Amgen is one of 30 companies comprising the Dow Jones Industrial Average®, and part of the Nasdaq-100 Index®. In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes. For more information, visit Amgen.com and follow us on X, LinkedIn, Instagram, TikTok, YouTube and Threads. 🔗 Community Guidelines: https://wwwext.amgen.com/community-guidelines 🔗Global Privacy Statement Directory: www.amgen.com/dp Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
Latest updates, reports, and threat intel affecting the global network.
At ETCISO Secufest 2026, cybersecurity and privacy leaders said boards now expect CISOs to translate resilience, trust, and regulatory risk...
The American AI Exports Programme will soon issue a public call for proposals from industry-led consortia to deliver integrated AI packages.
Blue Cloud Softech Solutions share price rose today after the company announced a strategic Memorandum of Understanding (MoU) with ConnectM...
Mangalore Today | Latest main news of mangalore, udupi - Page Mangaluru-s-Jayshree-Ullal-tops-list-of-India-s-richest-women-entrepreneurs.
Investors who applied for the TechD Cybersecurity IPO can check their allotment status online through the NSE or the registrar's website,...
In the early 2000s, data privacy and cybersecurity were still niche concerns in most organizations—rarely discussed in boardrooms and often...
Biocon Biologics Ltd., the subsidiary of Biocon Ltd., is now a forerunner in achieving an important milestone; the Pharmaceuticals and...
The three-day Bengaluru Tech Summit (BTS) 2024, held at the Bangalore Palace, concluded today with resounding success, breaking new ground...
Regulations play a vital role in shaping the cybersecurity landscape by setting clear standards for protecting sensitive data and ensuring...
ASE/Kalkitech ASE2000 V2 Communication Test Set 2.35 through 2.37 on Windows contains an improper certificate validation vulnerability in the IEC 60870-5-104 TLS client (Task Mode). This allows a network-positioned attacker to bypass certificate validation via a certificate with multiple simultaneous faults, enabling a Man-in-the-Middle attack on protected communications.
A vulnerability was found in Xuxueli xxl-job up to 3.4.2. Affected by this issue is some unknown functionality of the file xxl-job-admin/src/main/java/com/xxl/job/admin/business/controller/JobGroupController.java. The manipulation results in improper privilege management. The attack may be launched remotely. The exploit has been made public and could be used. The vendor was contacted early about this disclosure but did not respond in any way.
A vulnerability has been found in openstatusHQ openstatus up to f04c827112f30a11d571ebdad3892826034d6265. Affected by this vulnerability is an unknown functionality of the file apps/status-page/src/lib/proxy/resolve-custom-domain-rewrite.ts. The manipulation leads to server-side request forgery. The attack may be initiated remotely. This product uses a rolling release model to deliver continuous updates. As a result, specific version information for affected or updated releases is not available. The identifier of the patch is 86f370c9c20074c3c3fdec53a359874b8e670fd4. It is suggested to install a patch to address this issue. This issue got fixed with a silent patch.
SEP sesam before 5.2.0.24 mishandles User Authorization with MFA. If AD authentication is configured and MFA is enforced, an attacker can create a second OTP access capability. SEP sesam and Active Directory handle username capitalization differently, which may allow multiple SEP sesam user accounts to be created for the same Active Directory (AD) account. Active Directory treats usernames as case-insensitive, while SEP sesam distinguishes between different letter casing. As a result, the same AD user can be represented by multiple SEP sesam user accounts that differ only in username capitalization. When Active Directory authentication is configured and multi-factor authentication (MFA) is enforced, this behavior may allow an additional OTP Authenticator to be registered for the same AD account, reducing the effectiveness of MFA protection.
A flaw has been found in IOBit Uninstaller 15.5.0.11. Affected by this issue is the function sub_11838 of the file IURegistryFilter.sys of the component IOCTL Dispatch Handler. This manipulation causes null pointer dereference. The attack requires local access. The exploit has been published and may be used. Identical IURegistryFilter.sys ships across multiple IObit families. The vendor was contacted early about this disclosure but did not respond in any way.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.